Fate Therapeutics Inc. (FATE)
Fate Therapeutics Statistics
Share Statistics
Fate Therapeutics has 113.89M shares outstanding. The number of shares has increased by 14.77% in one year.
| Shares Outstanding | 113.89M |
| Shares Change (YoY) | 14.77% |
| Shares Change (QoQ) | 0.01% |
| Owned by Institutions (%) | 97.34% |
| Shares Floating | 97.88M |
| Failed to Deliver (FTD) Shares | 700 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 12.7M, so 11.15% of the outstanding shares have been sold short.
| Short Interest | 12.7M |
| Short % of Shares Out | 11.15% |
| Short % of Float | 12.98% |
| Short Ratio (days to cover) | 3.69 |
Valuation Ratios
The PE ratio is -2.29 and the forward PE ratio is -0.8. Fate Therapeutics's PEG ratio is 0.06.
| PE Ratio | -2.29 |
| Forward PE | -0.8 |
| PS Ratio | 5.79 |
| Forward PS | 2.9 |
| PB Ratio | 1 |
| P/FCF Ratio | -2.66 |
| PEG Ratio | 0.06 |
Enterprise Valuation
Fate Therapeutics Inc. has an Enterprise Value (EV) of 429.72M.
| EV / Earnings | -2.67 |
| EV / Sales | 6.76 |
| EV / EBITDA | -2.5 |
| EV / EBIT | -2.26 |
| EV / FCF | -3.1 |
Financial Position
The company has a current ratio of 8.48, with a Debt / Equity ratio of 0.28.
| Current Ratio | 8.48 |
| Quick Ratio | 8.48 |
| Debt / Equity | 0.28 |
| Total Debt / Capitalization | 21.94 |
| Cash Flow / Debt | -1.28 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.44% and return on capital (ROIC) is -40.37%.
| Return on Equity (ROE) | -0.44% |
| Return on Assets (ROA) | -0.32% |
| Return on Capital (ROIC) | -40.37% |
| Revenue Per Employee | 351.01K |
| Profits Per Employee | -889.1K |
| Employee Count | 181 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -85.53% in the last 52 weeks. The beta is 2.02, so Fate Therapeutics's price volatility has been higher than the market average.
| Beta | 2.02 |
| 52-Week Price Change | -85.53% |
| 50-Day Moving Average | 1.45 |
| 200-Day Moving Average | 2.93 |
| Relative Strength Index (RSI) | 38.31 |
| Average Volume (20 Days) | 2.74M |
Income Statement
In the last 12 months, Fate Therapeutics had revenue of 63.53M and earned -160.93M in profits. Earnings per share was -1.64.
| Revenue | 63.53M |
| Gross Profit | -98.16M |
| Operating Income | -190.51M |
| Net Income | -160.93M |
| EBITDA | -172.23M |
| EBIT | -190.51M |
| Earnings Per Share (EPS) | -1.64 |
Balance Sheet
The company has 41.87M in cash and 103.54M in debt, giving a net cash position of -61.67M.
| Cash & Cash Equivalents | 41.87M |
| Total Debt | 103.54M |
| Net Cash | -61.67M |
| Retained Earnings | -1.21B |
| Total Assets | 494.97M |
| Working Capital | 272.87M |
Cash Flow
In the last 12 months, operating cash flow was -132.26M and capital expenditures -6.15M, giving a free cash flow of -138.42M.
| Operating Cash Flow | -132.26M |
| Capital Expenditures | -6.15M |
| Free Cash Flow | -138.42M |
| FCF Per Share | -1.41 |
Margins
Gross margin is -154.51%, with operating and profit margins of -299.86% and -253.3%.
| Gross Margin | -154.51% |
| Operating Margin | -299.86% |
| Pretax Margin | -253.3% |
| Profit Margin | -253.3% |
| EBITDA Margin | -271.09% |
| EBIT Margin | -299.86% |
| FCF Margin | -217.86% |
Dividends & Yields
FATE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -146.43% |
| FCF Yield | -108.51% |
Analyst Forecast
The average price target for FATE is $6, which is 435.7% higher than the current price. The consensus rating is "Hold".
| Price Target | $6 |
| Price Target Difference | 435.7% |
| Analyst Consensus | Hold |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -3.8 |
| Piotroski F-Score | 2 |